Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
3,857
Views
0
CrossRef citations to date
0
Altmetric
Review

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference

Fabiana Greguccia Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA;b Department of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti, Bari, ItalyORCID Iconhttps://orcid.org/0000-0002-9947-9650View further author information
ORCID Icon,
Sheila Spadaa Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-8644-2237View further author information
ORCID Icon,
Mary Helen Barcellos-Hoffc Department of Radiation Oncology, School of Medicine, University of California, San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-5994-9558View further author information
ORCID Icon,
Nina Bhardwajd Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;e Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-1865-4187View further author information
ORCID Icon,
Charleen Chan Wah Hakf Translational Immunotherapy Team, The Institute of Cancer Research, London, UKORCID Iconhttps://orcid.org/0000-0002-6386-5699View further author information
ORCID Icon,
Alba Fiorentinob Department of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti, Bari, Italy;g Department of Medicine and Surgery, LUM University, Casamassima, Bari, ItalyORCID Iconhttps://orcid.org/0000-0003-4201-5852View further author information
ORCID Icon,
Chandan Guhah Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USAORCID Iconhttps://orcid.org/0000-0002-1906-2186View further author information
ORCID Icon,
Monica L. Guzmani Division of Hematology/Oncology, Department of Medicine, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA;j Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USAView further author information
,
Kevin Harringtonk The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, UKORCID Iconhttps://orcid.org/0000-0002-6014-348XView further author information
ORCID Icon,
Fernanda G. Herreral Centre Hospitalier Universitaire Vaudois, University of Lausanne and Ludwig Institute for Cancer Research at the Agora Cancer Research Center, Lausanne, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-7984-0472View further author information
ORCID Icon,
Jamie Honeychurchm Division of Cancer Sciences, University of Manchester, Manchester, UKORCID Iconhttps://orcid.org/0000-0001-6938-0839View further author information
ORCID Icon,
Theodore Hongn Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-8481-6581View further author information
ORCID Icon,
Lorea Iturrio Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, Signalisation Radiobiologie et Cancer, Orsay, FranceORCID Iconhttps://orcid.org/0000-0002-7911-3117View further author information
ORCID Icon,
Elisabeth Jaffeep Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USAView further author information
,
Sana D. Karamq Department of Radiation Oncology, University of Colorado, Aurora, CO, USAORCID Iconhttps://orcid.org/0000-0003-1676-5967View further author information
ORCID Icon,
Simon R.V. Knottr Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USAView further author information
,
Constantinos Koumeniss Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0001-5945-4726View further author information
ORCID Icon,
David Lydent Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-0193-4131View further author information
ORCID Icon,
Ariel E. Marciscanoa Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-8838-2127View further author information
ORCID Icon,
Alan Melcheru Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UKORCID Iconhttps://orcid.org/0000-0002-2042-3380View further author information
ORCID Icon,
Michele Mondiniv Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France;w Université of Paris-Saclay, Saclay, France;x INSERM U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0001-5803-0083View further author information
ORCID Icon,
Anna Mondinoy Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, ItalyORCID Iconhttps://orcid.org/0000-0003-0833-6927View further author information
ORCID Icon,
Zachary S. Morrisz Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAORCID Iconhttps://orcid.org/0000-0001-5558-3547View further author information
ORCID Icon,
Sean Pitrodaaa Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL, USAORCID Iconhttps://orcid.org/0000-0003-3056-7991View further author information
ORCID Icon,
Sergio A. Quezadabb Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UKORCID Iconhttps://orcid.org/0000-0002-9763-1700View further author information
ORCID Icon,
Laura Santambrogioa Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA;j Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA;cc Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-4674-7041View further author information
ORCID Icon,
Stephen Shiaodd Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0001-7586-2885View further author information
ORCID Icon,
John Staggee Centre de Recherche du Centre Hospitalier de l’Universite de Montreal, Faculty of Pharmacy, Montreal, CanadaORCID Iconhttps://orcid.org/0000-0001-7833-4228View further author information
ORCID Icon,
Irma Telarovicff Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, Zurich, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-1657-4650View further author information
ORCID Icon,
Robert Timmermangg Departments of Radiation Oncology and Neurosurgery, University of Texas Southwestern Medical Center, Dallas, TX, USAORCID Iconhttps://orcid.org/0000-0003-2462-1007View further author information
ORCID Icon,
Marie-Catherine Vozeninhh Laboratory of Radiation Oncology, Radiation Oncology Service, Department of Oncology, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-2109-8073View further author information
ORCID Icon,
Ralph Weichselbaumii Department of Radiation and Cellular Oncology, Ludwig Center for Metastases Research, University of Chicago, IL, USAORCID Iconhttps://orcid.org/0000-0002-5643-8939View further author information
ORCID Icon,
James Welshjj The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Anna Wilkinskk Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, Sutton, UKORCID Iconhttps://orcid.org/0000-0002-0425-584XView further author information
ORCID Icon,
Chris Xull School of Applied and Engineering Physics, Cornell University, Ithaca, NY, USAORCID Iconhttps://orcid.org/0000-0002-3493-6427View further author information
ORCID Icon,
Roberta Zappasodimm Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA;nn Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA;oo Parker Institute for Cancer Immunotherapy, San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-7031-6671View further author information
ORCID Icon,
Weiping Zoupp Departments of Surgery and Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USAORCID Iconhttps://orcid.org/0000-0001-7952-3549View further author information
ORCID Icon,
Alexandre Bobardqq Gustave Roussy Cancer Campus, Villejuif, FranceView further author information
,
Sandra Demariaa Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA;rr Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USACorrespondence[email protected]
View further author information
,
Lorenzo Galluzzia Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA;j Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA;cc Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2257-8500View further author information
ORCID Icon,
Eric Deutschv Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France;w Université of Paris-Saclay, Saclay, France;x INSERM U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, FranceCorrespondence[email protected]
View further author information
&
Silvia C. Formentia Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA;j Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8227-8924View further author information
ORCID Icon show all
Article: 2222560 | Received 14 Apr 2023, Accepted 02 Jun 2023, Published online: 21 Jun 2023

References

  • Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–10. doi:10.1016/j.cell.2015.03.030.
  • Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509–528. doi:10.1038/s41573-021-00345-8.
  • Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459). doi:10.1126/scitranslmed.aat7807.
  • Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680. doi:10.1038/s41568-020-0285-7.
  • Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–265. doi:10.1093/jnci/djs629.
  • Deutsch E, Chargari C, Galluzzi L, Kroemer G. Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol. 2019;20(8):e452–e463. doi:10.1016/S1470-2045(19)30171-8.
  • Formenti SC, Demaria S. Future of radiation and immunotherapy. Int J Radiat Oncol. 2020;108(1):3–5. doi:10.1016/j.ijrobp.2020.04.034.
  • Golden EB, Marciscano AE, Formenti SC. Radiation therapy and the in situ vaccination approach. Int J Radiat Oncol Biol Phys. 2020;108(4):891–898. doi:10.1016/j.ijrobp.2020.08.023.
  • Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84(4):879–880. doi:10.1016/j.ijrobp.2012.06.020.
  • Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol. 2020;21(2):120–134. doi:10.1038/s41590-019-0561-4.
  • Cytlak UM, Dyer DP, Honeychurch J, Williams KJ, Travis MA, Illidge TM. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol. 2022;22(2):124–138. doi:10.1038/s41577-021-00568-1.
  • Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15(8):477–494. doi:10.1038/s41571-018-0046-7.
  • Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023. doi:10.1038/s41571-023-00782-x.
  • Klapp V, Álvarez-Abril B, Leuzzi G, Kroemer G, Ciccia A, Galluzzi L. The DNA damage response and inflammation in cancer. Cancer Discov. 2023;OF1–OF25. IN PRESS. doi:10.1158/2159-8290.CD-22-1220.
  • Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ. Radiosensitization by the ATR Inhibitor AZD6738 through generation of acentric micronuclei. Mol Cancer Ther. 2017;16(1):25–34. doi:10.1158/1535-7163.MCT-16-0239.
  • Dillon MT, Bergerhoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin EC, Pearson A, Smith HG, Paget JTE, Patel RR, et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin Cancer Res. 2019;25(11):3392–3403. doi:10.1158/1078-0432.CCR-18-1821.
  • Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, et al. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade. J ImmunoTher Cancer. 2022;10(3):e004306. doi:10.1136/jitc-2021-004306.
  • Tuomela K, Mukherjee D, Ambrose AR, Harikrishnan A, Mole H, Hurlstone A, Önfelt B, Honeychurch J, Davis DM. Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity. Proc Natl Acad Sci U S A. 2022;119(3). doi:10.1073/pnas.2111900119.
  • Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the game in immunotherapy. Trends in Cancer. 2016;2(6):286–294. doi:10.1016/j.trecan.2016.05.002.
  • Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, et al. Low-Dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12(1):108–133. doi:10.1158/2159-8290.CD-21-0003.
  • Zhao L, Zhang S, Kepp O, Kroemer G, Liu P. Dendritic cell transfer for cancer immunotherapy. Int Rev Cell Mol Biol. 2022;370:33–64.
  • Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J ImmunoTher Cancer. 2020;8(2):e000537. doi:10.1136/jitc-2020-000537.
  • Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, et al. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021;162:60–67. doi:10.1016/j.radonc.2021.06.037.
  • Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, et al. CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat Cancer. 2020;1(12):1153–1166. doi:10.1038/s43018-020-00133-0.
  • Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S, et al. CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours. Nature. 2021;591(7851):652–658. doi:10.1038/s41586-021-03326-4.
  • Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, Thel H, Hoyos D, Mehta A, Arshad S, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2(11):1124–1135. doi:10.1038/s43018-021-00269-7.
  • Roudko V, Bozkus CC, Orfanelli T, McClain CB, Carr C, O’Donnell T, Chakraborty L, Samstein R, Huang K-L, Blank SV, et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell. 2020;183(6):1634–1649.e1617. doi:10.1016/j.cell.2020.11.004.
  • Popovic A, Jaffee EM, Zaidi N. Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest. 2018;128(8):3209–3218. doi:10.1172/JCI120775.
  • Gartrell RD, Enzler T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX, Minns HE, Perni S, Weisberg SP, Rizk EM, et al. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Oncoimmunology. 2022;11(1):2066767. doi:10.1080/2162402X.2022.2066767.
  • Cao X, Lai SWT, Chen S, Wang S, Feng M. Targeting tumor-associated macrophages for cancer immunotherapy. Int Rev Cell Mol Biol. 2022;368:61–108.
  • Papachristoforou E, Ramachandran P. Macrophages as key regulators of liver health and disease. Int Rev Cell Mol Biol. 2022;368:143–212.
  • Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152–164. doi:10.1038/s41591-020-1131-x.
  • Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PMH, Lin J-C, Razaq MA, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–462. doi:10.1016/S1470-2045(20)30737-3.
  • Darragh LB, Gadwa J, Pham TT, Van Court B, Neupert B, Olimpo NA, Nguyen K, Nguyen D, Knitz MW, Hoen M, et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun. 2022;13(1):7015. doi:10.1038/s41467-022-34676-w.
  • Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res. 2018;24(20):5058–5071. doi:10.1158/1078-0432.CCR-17-3427.
  • Telarovic I, Yong CSM, Guckenberger M, Unkelbach J, Pruschy M. Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model. Neoplasia. 2022;31:100812. doi:10.1016/j.neo.2022.100812.
  • Santa-Maria CA, Dunn SA, Ho AY. Immunotherapy combined with radiation therapy in breast cancer: a rapidly evolving landscape. Semin Radiat Oncol. 2022;32(3):291–297. doi:10.1016/j.semradonc.2022.01.001.
  • Roschewski M, Longo DL, Wilson WH. CAR T-Cell therapy for large B-Cell lymphoma — who, when, and how? N Engl J Med. 2022;386(7):692–696. doi:10.1056/NEJMe2118899.
  • Antonana-Vildosola A, Zanetti SR, Palazon A. Enabling CAR-T cells for solid tumors: rage against the suppressive tumor microenvironment. Int Rev Cell Mol Biol. 2022;370:123–147.
  • Laurent PA, Morel D, Meziani L, Depil S, Deutsch E. Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. Oncoimmunology. 2023;12(1):2158013. doi:10.1080/2162402X.2022.2158013.
  • Gonzalez-Navarro EA, et al. What will (and should) be improved in CAR immunotherapy? Int Rev Cell Mol Biol. 2022;370:149–161. doi:10.1016/bs.ircmb.2022.04.002
  • Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-el-Enein M. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342–355. doi:10.1038/s41571-022-00607-3.
  • Yamazaki T, Sugita M, Martinet J, Boyer O, Galluzzi L, Guzman ML, Formenti SC. Boosting CAR T cell expansion and therapeutic activity with low-dose radiation therapy. Int J Radiat Oncol. 2020;108(3):S158–S159. doi:10.1016/j.ijrobp.2020.07.920.
  • Sugita M, Yamazaki T, Alhomoud M, Martinet J, Latouche J-B, Golden E, Boyer O, Van Besien K, Formenti SC, Galluzzi L, et al. Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell Death Disease. 2023;14(5):IN PRESS. doi: 10.1038/s41419-023-05829-6.
  • DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, Sadelain M. Low-Dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 2018;26(11):2542–2552. doi:10.1016/j.ymthe.2018.09.008.
  • Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, et al. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022;3(12):1498–1512. doi:10.1038/s43018-022-00467-x.
  • Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. doi:10.1038/nature14292.
  • Chen HY, Xu L, Li L-F, Liu X-X, Gao J-X, Bai Y-R. Inhibiting the CD8(+) T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance. Sci Rep. 2018;8(1):11934. doi:10.1038/s41598-018-30417-6.
  • Shiao SL, Kershaw KM, Limon JJ, You S, Yoon J, Ko EY, Guarnerio J, Potdar AA, McGovern DPB, Bose S, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell. 2021;39(9):1202–1213.e1206. doi:10.1016/j.ccell.2021.07.002.
  • Man SM, Jenkins BJ. Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer. 2022;22(7):397–413. doi:10.1038/s41568-022-00462-5.
  • Dixson AC, Dawson TR, Di Vizio D, Weaver AM. Context-specific regulation of extracellular vesicle biogenesis and cargo selection. Nat Rev Mol Cell Biol. 2023. doi:10.1038/s41580-023-00576-0.
  • Wang G, Zhang H, Lyden D. Tumour-regulated anorexia preceding cachexia. Nat Cell Biol. 2021;23(2):111–113. doi:10.1038/s41556-021-00635-8.
  • Choi J, Cho HY, Jeon J, Kim K-A, Han YD, Ahn JB, Wortzel I, Lyden D, Kim HS. Detection of circulating KRAS mutant DNA in extracellular vesicles using droplet digital PCR in patients with colon cancer. Front Oncol. 2022;12:1067210. doi:10.3389/fonc.2022.1067210.
  • Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–335. doi:10.1038/nature15756.
  • Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182(4):1044–1061.e1018. doi:10.1016/j.cell.2020.07.009.
  • Clement CC, D’Alessandro A, Thangaswamy S, Chalmers S, Furtado R, Spada S, Mondanelli G, Ianni F, Gehrke S, Gargaro M, et al. 3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. Nat Commun. 2021;12(1):4447. doi:10.1038/s41467-021-24785-3.
  • Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17(10):611–629. doi:10.1038/s41571-020-0382-2.
  • Kepp O, Bezu L, Yamazaki T, Di Virgilio F, Smyth MJ, Kroemer G, Galluzzi L. ATP and cancer immunosurveillance. Embo J. 2021;40(13):e108130. doi:10.15252/embj.2021108130.
  • Wennerberg E, Spada S, Rudqvist N-P, Lhuillier C, Gruber S, Chen Q, Zhang F, Zhou XK, Gross SS, Formenti SC, et al. CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection. Cancer Immunol Res. 2020;8(4):465–478. doi:10.1158/2326-6066.CIR-19-0449.
  • Tsukui H, Horie H, Koinuma K, Ohzawa H, Sakuma Y, Hosoya Y, Yamaguchi H, Yoshimura K, Lefor AK, Sata N, et al. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model. Bmc Cancer. 2020;20(1):411. doi:10.1186/s12885-020-06893-3.
  • Jacoberger-Foissac C, Cousineau I, Bareche Y, Allard D, Chrobak P, Allard B, Pommey S, Messaoudi N, McNicoll Y, Soucy G, et al. CD73 inhibits cgas–sting and cooperates with cd39 to promote pancreatic cancer. Cancer Immunol Res. 2023;11(1):56–71. doi:10.1158/2326-6066.CIR-22-0260.
  • Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, et al. Resistance to Radiotherapy and PD-L1 Blockade is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res. 2018;24(21):5368–5380. doi:10.1158/1078-0432.CCR-18-1038.
  • Knitz MW, Bickett TE, Darragh LB, Oweida AJ, Bhatia S, Van Court B, Bhuvane S, Piper M, Gadwa J, Mueller AC, et al. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. J ImmunoTher Cancer. 2021;9(4):e001955. doi:10.1136/jitc-2020-001955.
  • Gonzalez-Junca A, Reiners O, Borrero-Garcia LD, Beckford-Vera D, Lazar AA, Chou W, Braunstein S, VanBrocklin H, Franc BL, Barcellos-Hoff MH. Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors. Int J Radiat Oncol Biol Phys. 2021;109(2):527–539. doi:10.1016/j.ijrobp.2020.09.043.
  • Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, et al. Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018;24(11):2493–2504. doi:10.1158/1078-0432.CCR-17-3322.
  • Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, Yeung T-L, Hasheminasab S-M, Jenkins MH, Meister S, et al. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39(10):1388–1403.e1310. doi:10.1016/j.ccell.2021.08.008.
  • Rodriguez-Ruiz ME, Rodríguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, Ponz-Sarvise M, Azpilikueta A, Bolaños E, Sanmamed MF, et al. TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. Mol Cancer Ther. 2019;18(3):621–631. doi:10.1158/1535-7163.MCT-18-0558.
  • Liu Q, Palomero L, Moore J, Guix I, Espín R, Aytés A, Mao J-H, Paulovich AG, Whiteaker JR, Ivey RG, et al. Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types. Sci Transl Med. 2021;13(580). doi:10.1126/scitranslmed.abc4465.
  • Liu Q, Ma L, Jones T, Palomero L, Pujana MA, Martinez-Ruiz H, Ha PK, Murnane J, Cuartas I, Seoane J, et al. Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. Clin Cancer Res. 2018;24(23):6001–6014. doi:10.1158/1078-0432.CCR-18-1346.
  • Formenti SC, Rudqvist N-P, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–1851. doi:10.1038/s41591-018-0232-2.
  • Lhuillier C, Rudqvist N-P, Yamazaki T, Zhang T, Charpentier M, Galluzzi L, Dephoure N, Clement CC, Santambrogio L, Zhou XK, et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. 2021;131(5). doi:10.1172/JCI138740.
  • Ban Y, Markowitz GJ, Zou Y, Ramchandani D, Kraynak J, Sheng J, Lee SB, Wong STC, Altorki NK, Gao D, et al. Radiation-activated secretory proteins of Scgb1a1(+) club cells increase the efficacy of immune checkpoint blockade in lung cancer. Nat Cancer. 2021;2(9):919–931. doi:10.1038/s43018-021-00245-1.
  • Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33(3):463–479.e410. doi:10.1016/j.ccell.2018.01.011.
  • Wilkins A, Fontana E, Nyamundanda G, Ragulan C, Patil Y, Mansfield D, Kingston J, Errington-Mais F, Bottomley D, von Loga K, et al. Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. J ImmunoTher Cancer. 2021;9(3):e001717. doi:10.1136/jitc-2020-001717.
  • Jimenez-Cortegana C, Galassi C, Klapp V, Gabrilovich DI, Galluzzi L. Myeloid-Derived Suppressor Cells and Radiotherapy. Cancer Immunol Res. 2022;10(5):545–557. doi:10.1158/2326-6066.CIR-21-1105.
  • Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, Zheng W, Mauceri H, Mack M, Xu M, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun. 2017;8(1):1736. doi:10.1038/s41467-017-01566-5.
  • Rao E, Hou Y, Huang X, Wang L, Wang J, Zheng W, Yang H, Yu X, Yang K, Bugno J, et al. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021;6(60). doi:10.1126/sciimmunol.aba8426.
  • Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, Azria D. Clinical radioimmunotherapy—the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720–734. doi:10.1038/nrclinonc.2011.160.
  • Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13(602). doi:10.1126/scitranslmed.abb3631.
  • Morris ZS, Guy EI, Werner LR, Carlson PM, Heinze CM, Kler JS, Busche SM, Jaquish AA, Sriramaneni RN, Carmichael LL, et al. Tumor-Specific Inhibition of in situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res. 2018;6(7):825–834. doi:10.1158/2326-6066.CIR-17-0353.
  • Kerr CP, Grudzinski JJ, Nguyen TP, Hernandez R, Weichert JP, Morris ZS. Developments in combining targeted radionuclide therapies and immunotherapies for cancer treatment. Pharmaceutics. 2022;15(1):128. doi:10.3390/pharmaceutics15010128.
  • Magee K, Marsh IR, Turek MM, Grudzinski J, Aluicio-Sarduy E, Engle JW, Kurzman ID, Zuleger CL, Oseid EA, Jaskowiak C, et al. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLos One. 2021;16(8):e0255798. doi:10.1371/journal.pone.0255798.
  • Kacem H, Almeida A, Cherbuin N, Vozenin MC. Understanding the FLASH effect to unravel the potential of ultra-high dose rate irradiation. Int J Radiat Biol. 2022;98(3):506–516. doi:10.1080/09553002.2021.2004328.
  • Vozenin MC, Bourhis J, Durante M. Towards clinical translation of FLASH radiotherapy. Nat Rev Clin Oncol. 2022;19(12):791–803. doi:10.1038/s41571-022-00697-z.
  • Renaudin X. Reactive oxygen species and DNA damage response in cancer. Int Rev Cell Mol Biol. 2021;364:139–161.
  • Iturri L, et al. Proton FLASH radiation therapy and immune infiltration: evaluation in an orthotopic glioma rat model. Int J Radiat Oncol Biol Phys. 2022.
  • Bertho A, Iturri L, Brisebard E, Juchaux M, Gilbert C, Ortiz R, Sebrie C, Jourdain L, Lamirault C, Ramasamy G, et al. Evaluation of the role of the immune system response after minibeam radiation therapy. Int J Radiat Oncol Biol Phys. 2023;115(2):426–439. doi:10.1016/j.ijrobp.2022.08.011.
  • Diffenderfer ES, Verginadis II, Kim MM, Shoniyozov K, Velalopoulou A, Goia D, Putt M, Hagan S, Avery S, Teo K, et al. Design, implementation, and in vivo validation of a novel proton flash radiation therapy system. Int J Radiat Oncol Biol Phys. 2020;106(2):440–448. doi:10.1016/j.ijrobp.2019.10.049.
  • Morris Z, Dohopolski M, Rahimi A, Timmerman R. Future directions in the use of sabr for the treatment of oligometastatic cancers. Semin Radiat Oncol. 2021;31(3):253–262. doi:10.1016/j.semradonc.2021.03.004.
  • Moore C, Hsu C-C, Chen W-M, Chen BPC, Han C, Story M, Aguilera T, Pop LM, Hannan R, Fu Y-X, et al. Personalized ultrafractionated stereotactic adaptive radiotherapy (pulsar) in preclinical models enhances single-agent immune checkpoint blockade. Int J Radiat Oncol Biol Phys. 2021;110(5):1306–1316. doi:10.1016/j.ijrobp.2021.03.047.
  • Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Semin Cancer Biol. 2018;52:125–134. doi:10.1016/j.semcancer.2017.12.007.
  • Huang EP, O’Connor JPB, McShane LM, Giger ML, Lambin P, Kinahan PE, Siegel EL, Shankar LK. Criteria for the translation of radiomics into clinically useful tests. Nat Rev Clin Oncol. 2023;20(2):69–82. doi:10.1038/s41571-022-00707-0.
  • Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180–1191. doi:10.1016/S1470-2045(18)30413-3.
  • Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, Milic M, Carré A, Battistella E, Alvarez Andres E, et al. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. J ImmunoTher Cancer. 2020;8(2):e001429. doi:10.1136/jitc-2020-001429.
  • Choe K, Hontani Y, Wang T, Hebert E, Ouzounov DG, Lai K, Singh A, Béguelin W, Melnick AM, Xu C. Intravital three-photon microscopy allows visualization over the entire depth of mouse lymph nodes. Nat Immunol. 2022;23(2):330–340. doi:10.1038/s41590-021-01101-1.
  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa1809697.
  • Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–1203. doi:10.1056/NEJMoa2032125.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.